Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal) (TA960)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 March 2024
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (TA953)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 March 2024
Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal) (TA941)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 December 2023
Idebenone for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over [ID547]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 19 June 2024
Faricimab for treating macular oedema caused by retinal vein occlusion [ID6197]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 14 August 2024
Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
ONS-5010 for treating wet age-related macular degeneration ID6320Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pegcetacoplan for treating geographic atrophy [ID4041]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration ID6401Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ciclosporin ophthalmic solution for treating dry eyes after inadequate response to artificial tears TSID8472Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC